8-K: CalciMedica Secures $55 Million in Private Placement to Advance Clinical Programs

CalciMedica has announced a private placement to raise up to $55 million to fund its clinical trials for Auxora in acute pancreatitis and acute kidney injury.

Summary

• CalciMedica has entered into a securities purchase agreement for a private placement to raise up to approximately $55 million.
• The financing includes an initial upfront funding of $20.4 million.
• There is a potential to receive an additional approximately $34.2 million upon exercise of accompanying warrants.
• The purchase price is $3.70 per share and accompanying warrants, or $4.3915 per share and accompanying warrants for directors, employees or consultants.
• Pre-funded warrants are available at a combined price of $3.6999 or $4.3914 per pre-funded warrant and accompanying warrants, with an exercise price of $0.0001 per share.
• The warrants are split into two tranches: Tranche A exercisable at $5.36 per share and Tranche B exercisable at $7.15 per share.
• Tranche A warrants expire 30 days after the announcement of topline data from the Phase 2b CARPO trial or December 31, 2024, whichever is earlier.
• Tranche B warrants expire 30 days after the announcement of topline data from the planned Phase 2 AKI trial or December 31, 2026, whichever is earlier.
• The initial closing is expected on or about January 23, 2024, and the second closing on or about February 5, 2024.
• The company intends to use the funds to support ongoing and planned Phase 2 clinical trials for Auxora in acute pancreatitis and acute kidney injury.
• The aggregate net proceeds, assuming full warrant exercise, are expected to fund subsequent clinical trials and other work in the AP and AKI programs.

Sentiment

Score: 8

Explanation: The document is generally positive, highlighting a successful capital raise and the advancement of clinical programs. The participation of new investors and the potential for significant funding are strong positives. However, the reliance on warrant exercises for full funding and the inherent risks of clinical development temper the overall sentiment.

Positives

• The private placement provides significant funding to advance CalciMedica's clinical programs.
• The participation of new healthcare-dedicated investors indicates confidence in the company's prospects.
• The funding will enable the initiation of clinical trials in AKI, a condition with significant unmet medical need.
• The aggregate net proceeds are expected to be sufficient to fund subsequent, potentially pivotal, clinical trials.

Negatives

• The exercise of warrants is required to realize the full $55 million in gross proceeds.
• The warrants are only exercisable in cash, except in limited circumstances, which may limit the amount of funds raised.
• The company is subject to certain restrictions on issuing additional equity or filing registration statements for a period of time.

Risks

• The company's expectations regarding the timing and completion of the private placement may not materialize.
• The company's ability to obtain and maintain regulatory approval for Auxora is subject to risk.
• Results from clinical trials may not be indicative of results that may be observed in the future.
• The company is subject to potential safety and other complications from Auxora.
• The company is subject to economic, business, competitive, and/or regulatory factors affecting the business of the Company generally.
• The company's ability to protect its intellectual property position is subject to risk.
• The company is subject to the impact of government laws and regulations.

Future Outlook

The company expects the aggregate net proceeds, assuming full warrant exercise, to fund subsequent clinical trials and other work in the AP and AKI programs. The company plans to initiate a Phase 2 study in acute kidney injury (AKI) in 1H 2024.

Management Comments

• We are excited about this vote of confidence from leading life science investors, which validates the progress we are making in the clinic with Auxora targeting acute inflammatory and immunologic diseases, said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica.
• This financing allows us to initiate clinical trials in AKI, a condition with significant unmet medical need, and brings us closer to our goal of making a meaningful difference in the lives of critically ill patients.

Industry Context

This private placement reflects the ongoing interest in companies developing novel therapies for inflammatory and immunologic diseases. The focus on acute pancreatitis and acute kidney injury highlights the unmet medical needs in these areas.

Comparison to Industry Standards

• The private placement structure, including the use of warrants, is a common method for raising capital in the biotech industry.
• The exercise prices of the warrants are set at a premium to the current share price, which is typical in such financings.
• The participation of healthcare-dedicated investors such as Deerfield Management, Soleus Capital, Stonepine Capital Management and Aisling Capital is a positive sign, as these firms are known for their expertise in the biotech sector.
• The use of a placement agent, JonesTrading Institutional Services LLC, is standard practice for private placements of this size.
• The company's stated intention to use the proceeds to fund clinical trials is consistent with the typical use of funds raised by clinical-stage biotech companies.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares and warrants.
• Employees may benefit from the company's increased financial stability and growth prospects.
• Patients may benefit from the development of new therapies for acute pancreatitis and acute kidney injury.
• Investors may benefit from the potential for future returns on their investment.

Next Steps

• The company expects the initial closing of the private placement on or about January 23, 2024.
• The company expects the second closing of the private placement on or about February 5, 2024.
• The company plans to initiate a Phase 2 study in acute kidney injury (AKI) in 1H 2024.
• The company expects topline data from the Phase 2b CARPO trial of Auxora in AP patients in the first half of 2024.
• The company expects additional data from the ongoing Phase 1/2 CRSPA AIPT study by 2H 2024.

Key Dates

Keywords

private placement, clinical trials, Auxora, acute pancreatitis, acute kidney injury, warrants, CRAC channel inhibition, biopharmaceutical, financing, securities